CD133 has been used to detect the CSCs of various malignant diseases, including leukemia, brain tumors, colon carcinoma, prostate cancer, liver carcinoma, lung cancer, pancreas carcinoma, and malignant melanoma. This evidence concerns the gene PROM1 and exocrine pancreatic carcinoma.